Clinical Trial Update: JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial evaluating JAB-23E73 in adults with KRAS-altered advanced solid tumors; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• JAB-23E73

Snippet

Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING